Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
11.55
+0.03 (0.26%)
At close: Aug 1, 2025, 4:00 PM
11.59
+0.04 (0.35%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $20, which forecasts a 73.16% increase in the stock price over the next year. The lowest target is $17 and the highest is $25.
Price Target: $20.00 (+73.16%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +47.19% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +47.19% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +116.45% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
68.39M
from 128.94M
Decreased by -46.96%
Revenue Next Year
32.30M
from 68.39M
Decreased by -52.77%
EPS This Year
-1.59
from -11.41
EPS Next Year
-2.79
from -1.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 103.1M | 63.0M | 63.0M | ||
| Avg | 68.4M | 32.3M | 23.6M | ||
| Low | 8.8M | 2.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -20.1% | -7.9% | 95.0% | ||
| Avg | -47.0% | -52.8% | -27.1% | ||
| Low | -93.2% | -95.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.38 | -0.04 | 1.47 | ||
| Avg | -1.59 | -2.79 | -3.14 | ||
| Low | -3.43 | -7.65 | -6.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.